The key to successful site and patient recruitment is having the ability to mine electronic health records as well as pharmacy, claims, laboratory and historical CRO recruitment data using proprietary search algorithms. Current research indicates that more than 25% of clinical trial sites are unproductive. Relying on a data-driven decision-making process will lead to far fewer non-productive clinical trial sites, shorter development timelines, greater patient recruitment and ultimately lower drug development costs.

With more clinical trials being conducted — and with the majority of them operating under delayed timelines — patient access has become the critical piece to solving what has become a very inefficient and costly puzzle known as drug development. While the process of drug development over the last few decades has been heavily driven by scientific methodology, the process by which clinical trials are conducted has consistently lacked the same rigor. Achieving successful patient access and meeting clinical trial timelines will require CROs to use more accurate processes for site selection and targeted patient enrollment.

Although having access to relevant data is important to enhancing site selection and patient recruitment, sponsors and CROs must also mine this data with algorithms that have been established to match planned patient populations and inclusion/exclusion criteria. When sponsors and CROs apply detailed search algorithms across multiple patient data platforms, they are able to find and target sites with the appropriate patient populations and confirm that the planned trial design matches customary care practices. This confirmation is the first step to both determining a trial’s feasibility and mining patient data. In addition, sponsor companies can use data-mining algorithms to determine if medical professionals are treating the target patient population as expected and to locate the patients by physician practice.

This audio conference will explore the power of mining EHR/EMR, lab, pharmacy, claims and historical CRO recruitment data. It will also review how using data-driven decision making to validate trial designs and patient and site selection is a key to successful drug development.

To register, click here.
Please make sure that when registering: you apply the following promotional code: PRA2010S

The deadline for registration is Wednesday,
21-July-2010.

SPEAKER

Kent Thoelke
Senior Vice President, Scientific and Medical Affairs, PRA International

Kent Thoelke is a highly trained global drug development professional with over 19 years of experience in the industry. He has extensive experience in the execution of all aspects of global studies, having led programs within biotech, pharma and the CRO industry. He has a comprehensive understanding of all stages of product development, including regulatory, manufacturing, CMC, preclinical and clinical aspects. He is currently listed as a co-inventor on 10 patents related to a high dose targeted radiotherapy, for which he led development efforts in hematologic malignancies. Mr. Thoelke is a leader in the development of evidence-based approaches in the field of clinical research, particularly the leveraging of data to more effectively target patient accrual into clinical trials. Having visited sites in over 35 countries, Mr. Thoelke is very familiar with the global clinical trials environment and customary care practices throughout the world, and has established relationships with therapeutic experts in numerous indications.